Is IDYA or ANRO more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets IDEAYA Biosciences N/A -14.24% -13.09% Alto Neuroscience N/A -47.22% -38.81%

Does the media prefer IDYA or ANRO?

In the previous week, Alto Neuroscience had 3 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 7 mentions for Alto Neuroscience and 4 mentions for IDEAYA Biosciences. Alto Neuroscience's average media sentiment score of 0.55 beat IDEAYA Biosciences' score of 0.48 indicating that Alto Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alto Neuroscience 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OGN or ANRO?

In the previous week, Alto Neuroscience had 3 more articles in the media than Organon & Co.. MarketBeat recorded 7 mentions for Alto Neuroscience and 4 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.08 beat Alto Neuroscience's score of 0.55 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ANRO or RARE?

In the previous week, Alto Neuroscience had 3 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 7 mentions for Alto Neuroscience and 4 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.91 beat Alto Neuroscience's score of 0.55 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARQT or ANRO?

In the previous week, Alto Neuroscience had 4 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 7 mentions for Alto Neuroscience and 3 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.85 beat Alto Neuroscience's score of 0.55 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ADPT or ANRO?

In the previous week, Alto Neuroscience had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 7 mentions for Alto Neuroscience and 5 mentions for Adaptive Biotechnologies. Alto Neuroscience's average media sentiment score of 0.55 beat Adaptive Biotechnologies' score of 0.51 indicating that Alto Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alto Neuroscience (ANRO) Competitors

$27.54 +0.21 (+0.78%)

Closing price 07/17/2026 03:59 PM Eastern

Extended Trading

$27.53 -0.01 (-0.05%)

As of 07/17/2026 07:26 PM Eastern

Compare

ANRO vs. IDYA, OGN, RARE, ARQT, and ADPT

Should you buy Alto Neuroscience stock or one of its competitors? MarketBeat compares Alto Neuroscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alto Neuroscience include IDEAYA Biosciences (IDYA), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), Arcutis Biotherapeutics (ARQT), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry.

How does Alto Neuroscience compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Alto Neuroscience (NYSE:ANRO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Alto Neuroscience has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.47	-$113.70M	-$1.60	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

IDEAYA Biosciences' return on equity of -14.24% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Alto Neuroscience	N/A	-47.22%	-38.81%

IDEAYA Biosciences has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

IDEAYA Biosciences presently has a consensus target price of $50.25, indicating a potential upside of 39.54%. Alto Neuroscience has a consensus target price of $35.25, indicating a potential upside of 27.98%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe IDEAYA Biosciences is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, Alto Neuroscience had 3 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 7 mentions for Alto Neuroscience and 4 mentions for IDEAYA Biosciences. Alto Neuroscience's average media sentiment score of 0.55 beat IDEAYA Biosciences' score of 0.48 indicating that Alto Neuroscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alto Neuroscience	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.3% of IDEAYA Biosciences shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

IDEAYA Biosciences beats Alto Neuroscience on 8 of the 14 factors compared between the two stocks.

How does Alto Neuroscience compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Alto Neuroscience (NYSE:ANRO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Alto Neuroscience had 3 more articles in the media than Organon & Co.. MarketBeat recorded 7 mentions for Alto Neuroscience and 4 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.08 beat Alto Neuroscience's score of 0.55 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alto Neuroscience	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 15.71%. Alto Neuroscience has a consensus target price of $35.25, suggesting a potential upside of 27.98%. Given Alto Neuroscience's stronger consensus rating and higher probable upside, analysts plainly believe Alto Neuroscience is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Organon & Co. has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.16B	0.58	$187M	$0.93	14.54
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

77.4% of Organon & Co. shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Organon & Co. has a net margin of 3.99% compared to Alto Neuroscience's net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Alto Neuroscience	N/A	-47.22%	-38.81%

Summary

Organon & Co. beats Alto Neuroscience on 10 of the 15 factors compared between the two stocks.

How does Alto Neuroscience compare to Ultragenyx Pharmaceutical?

Alto Neuroscience (NYSE:ANRO) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Alto Neuroscience has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Alto Neuroscience is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Ultragenyx Pharmaceutical	$673M	4.28	-$575M	-$6.11	N/A

Alto Neuroscience has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alto Neuroscience has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Alto Neuroscience's return on equity of -47.22% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

In the previous week, Alto Neuroscience had 3 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 7 mentions for Alto Neuroscience and 4 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.91 beat Alto Neuroscience's score of 0.55 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alto Neuroscience presently has a consensus price target of $35.25, suggesting a potential upside of 27.98%. Ultragenyx Pharmaceutical has a consensus price target of $58.41, suggesting a potential upside of 99.49%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Alto Neuroscience and Ultragenyx Pharmaceutical tied by winning 8 of the 16 factors compared between the two stocks.

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Alto Neuroscience (NYSE:ANRO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Alto Neuroscience has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Alto Neuroscience	N/A	-47.22%	-38.81%

Arcutis Biotherapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

In the previous week, Alto Neuroscience had 4 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 7 mentions for Alto Neuroscience and 3 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.85 beat Alto Neuroscience's score of 0.55 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alto Neuroscience	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has higher revenue and earnings than Alto Neuroscience. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$415.62M	8.57	-$16.14M	-$0.03	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Arcutis Biotherapeutics currently has a consensus target price of $34.00, suggesting a potential upside of 19.34%. Alto Neuroscience has a consensus target price of $35.25, suggesting a potential upside of 27.98%. Given Alto Neuroscience's stronger consensus rating and higher probable upside, analysts plainly believe Alto Neuroscience is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

Arcutis Biotherapeutics beats Alto Neuroscience on 7 of the 13 factors compared between the two stocks.

How does Alto Neuroscience compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Alto Neuroscience (NYSE:ANRO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Adaptive Biotechnologies currently has a consensus price target of $20.83, suggesting a potential downside of 9.10%. Alto Neuroscience has a consensus price target of $35.25, suggesting a potential upside of 27.98%. Given Alto Neuroscience's stronger consensus rating and higher probable upside, analysts plainly believe Alto Neuroscience is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Adaptive Biotechnologies has a beta of 2.07, indicating that its share price is 107% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Adaptive Biotechnologies has higher revenue and earnings than Alto Neuroscience. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	13.24	-$59.50M	-$0.33	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Alto Neuroscience has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Adaptive Biotechnologies' return on equity of -40.06% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Alto Neuroscience	N/A	-47.22%	-38.81%

99.2% of Adaptive Biotechnologies shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Alto Neuroscience had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 7 mentions for Alto Neuroscience and 5 mentions for Adaptive Biotechnologies. Alto Neuroscience's average media sentiment score of 0.55 beat Adaptive Biotechnologies' score of 0.51 indicating that Alto Neuroscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alto Neuroscience	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alto Neuroscience beats Adaptive Biotechnologies on 8 of the 15 factors compared between the two stocks.

Get Alto Neuroscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANRO vs. The Competition

Export

Metric	Alto Neuroscience	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$966.49M	$3.69B	$6.86B	$23.39B
Dividend Yield	N/A	2.17%	2.67%	4.16%
P/E Ratio	-11.38	21.03	27.25	30.95
Price / Sales	N/A	177.66	517.83	165.09
Price / Cash	N/A	154.08	52.99	31.95
Price / Book	5.66	8.26	10.69	4.76
Net Income	-$63.24M	$23.83M	$3.59B	$1.07B
7 Day Performance	4.07%	-3.47%	-2.20%	-0.01%
1 Month Performance	21.46%	2.69%	1.63%	1.08%
1 Year Performance	890.79%	45.93%	25.64%	16.70%

Alto Neuroscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANRO Alto Neuroscience	2.4728 of 5 stars	$27.54 +0.8%	$35.25 +28.0%	+890.8%	$966.49M	N/A	N/A	N/A	News Coverage Analyst Upgrade Gap Down
IDYA IDEAYA Biosciences	3.3017 of 5 stars	$40.51 +2.9%	$50.25 +24.0%	+66.8%	$3.56B	$218.71M	N/A	80	News Coverage Gap Down
OGN Organon & Co.	3.2664 of 5 stars	$13.51 -0.4%	$11.40 -15.6%	+43.0%	$3.55B	$6.22B	14.52	10,000	Positive News
RARE Ultragenyx Pharmaceutical	3.5846 of 5 stars	$35.87 +6.4%	$58.41 +62.8%	+11.3%	$3.53B	$673M	N/A	1,371	Gap Down
ARQT Arcutis Biotherapeutics	3.5426 of 5 stars	$27.67 +6.1%	$34.00 +22.9%	+94.2%	$3.46B	$376.07M	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANRO) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alto Neuroscience (ANRO) Competitors

ANRO vs. IDYA, OGN, RARE, ARQT, and ADPT

How does Alto Neuroscience compare to IDEAYA Biosciences?

Summary

How does Alto Neuroscience compare to Organon & Co.?

Summary

How does Alto Neuroscience compare to Ultragenyx Pharmaceutical?

Summary

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Summary

How does Alto Neuroscience compare to Adaptive Biotechnologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alto Neuroscience (ANRO) Competitors

ANRO vs. IDYA, OGN, RARE, ARQT, and ADPT

How does Alto Neuroscience compare to IDEAYA Biosciences?

Which has preferable valuation & earnings, IDYA or ANRO?

Is IDYA or ANRO more profitable?

Which has more risk & volatility, IDYA or ANRO?

Do analysts prefer IDYA or ANRO?

Does the media prefer IDYA or ANRO?

Do insiders and institutionals believe in IDYA or ANRO?

Summary

How does Alto Neuroscience compare to Organon & Co.?

Does the media prefer OGN or ANRO?

Which has more volatility & risk, OGN or ANRO?

Do analysts recommend OGN or ANRO?

Which has preferable earnings and valuation, OGN or ANRO?

Do institutionals and insiders have more ownership in OGN or ANRO?

Is OGN or ANRO more profitable?

Summary

How does Alto Neuroscience compare to Ultragenyx Pharmaceutical?

Which has higher earnings & valuation, ANRO or RARE?

Which has more risk and volatility, ANRO or RARE?

Do insiders and institutionals hold more shares of ANRO or RARE?

Is ANRO or RARE more profitable?

Does the media refer more to ANRO or RARE?

Do analysts recommend ANRO or RARE?

Summary

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Is ARQT or ANRO more profitable?

Which has more risk & volatility, ARQT or ANRO?

Does the media prefer ARQT or ANRO?

Which has preferable valuation and earnings, ARQT or ANRO?

Do analysts rate ARQT or ANRO?

Summary

How does Alto Neuroscience compare to Adaptive Biotechnologies?

Do analysts recommend ADPT or ANRO?

Which has more volatility & risk, ADPT or ANRO?

Which has preferable earnings and valuation, ADPT or ANRO?

Is ADPT or ANRO more profitable?

Do institutionals and insiders have more ownership in ADPT or ANRO?

Does the media favor ADPT or ANRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools